PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperglycemia |
| Phenotype | C0010481|cushing\'s syndrome |
| Sentences | 5 |
| PubMedID- 22674211 | Mifepristone (a glucocorticoid receptor antagonist) is another promising drug, recently approved by the fda for treatment of hyperglycemia associated with cushing's syndrome. |
| PubMedID- 22837948 | Could one have imagined, at that time, that this would go on to be used for treatment of an adrenal disorder, and one day be approved to control hyperglycemia in adults with endogenous cushing's syndrome? |
| PubMedID- 24765481 | Mifepristone was recently approved for the treatment of hyperglycemia associated with endogenous cushing's syndrome and has been shown to improve some of the metabolic abnormalities.14 this was not an approved treatment at the time of this case and it is unclear if this would have affected the outcome. |
| PubMedID- 23558873 | Background: mifepristone is approved to control hyperglycemia in adults with endogenous cushing's syndrome and is described as a mildly qtc prolonging drug, based on a tqt study. |
| PubMedID- 25560275 | Mifepristone, a glucocorticoid receptor antagonist, has been approved for hyperglycemia associated with cushing's syndrome based on the results of a prospective study where it produced in the majority of patients' significant clinical and metabolic improvement. |
Page: 1